#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    IgA nephropathy Methylmalonic acidaemia Small intestine neuroendocrine tumour Monogenic diabetes Familial hypertriglyceridaemia Aspergillus infection Tuberous sclerosis complex Cardiac sarcoidosis Cystic fibrosis gastrointestinal disease Biotinidase deficiency Prodromal Alzheimer's disease Hyperphagia B-cell lymphoma recurrent Arrhythmia Cortical dysplasia More trials…

    Learn about Rare Diseases

    Factor IX deficiency – Life with Disease Rhabdomyosarcoma recurrent Propionic acidaemia – Life with Disease Encephalitis autoimmune Pemphigoid Extranodal marginal zone B-cell lymphoma (MALT type) Vascular malformation – Treatment CADASIL – Basic Information Pulmonary sarcoidosis – Trials in Disease Tuberous sclerosis complex – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Allo-501A AMMONIUM (15N) CHLORIDE Pertuzumab Cipaglucosidase Alfa Potassium Canrenoate Pal1-15 Acetate Dexpanthenol Fluticasone Propylene Glycol Bupivacaine Ozanimod Cenegermin Anv600 DAPIGLUTIDE Sotalol Hydrochloride RO7284755 GXV813 Thiamine Nitrate Bp Quavonlimab Sertindole More therapies…

    Learn about Your Condition

    Appendicitis Alagille syndrome Primary amyloidosis Paraesthesia Graft infection Extraskeletal ossification Breast cancer metastatic Femoral hernia Antisynthetase syndrome Wiskott-Aldrich syndrome Chronic lymphocytic leukaemia Shock Renal cancer recurrent HER2 negative breast cancer Endocarditis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Somogy Varmegyei Kaposi Mor Oktato Korhaz

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Tallian Gyula Utca 20-32, Kaposvar, 7400, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Bulgaria France Germany Greece Hungary +4

  • Study of Pirtobrutinib, Venetoclax and Rituximab combination compared to Venetoclax and Rituximab in previously treated Chronic Lymphocytic Leukemia patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Pirtobrutinib
    • Rituximab
    • Venetoclax
    Belgium Czechia Denmark France Germany Hungary +5

  • Study on Extended Access to Momelotinib for Patients with Myelofibrosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Momelotinib Dihydrochloride Monohydrate
    Belgium Bulgaria Denmark France Germany Hungary +4

  • Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Acalabrutinib
    • Chlorambucil
    • Obinutuzumab
    Belgium France Germany Hungary Italy Lithuania +3

  • Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Golcadomide
    • Pegfilgrastim
    • Apixaban
    Austria Bulgaria Czechia Denmark Finland France +11

  • Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Bimekizumab
    • Ustekinumab
    Belgium Czechia France Germany Hungary Italy +2

  • Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Upadacitinib
    Belgium Bulgaria Germany Hungary Italy The Netherlands +4

  • Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Upadacitinib
    Austria Belgium Bulgaria Croatia Czechia Finland +12

  • Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • Pembrolizumab
    Bulgaria Czechia Finland France Germany Greece +8

  • Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Deep vein thrombosis
    • Thrombolysis
    Investigated Drugs:
    • Bay 3018250
    Belgium Bulgaria Czechia France Germany Greece +5
Previous Page
1 … 7 8 9 10 11 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!